top of page

Investigating the efficacy, safety, and tolerability of ML-004 in autistic adolescents 

We are working with Maplight and other sites around Australia, Canada, and the United States, to investigate the safety, tolerability, and efficacy of a pharmaceutical therapy called ML-004.

We are looking to find out whether ML-004
might address the characteristics of autism that can make social interaction challenging.

Recruitment

To be eligible, participants must be:

  • Be aged 12-17 years old 

  • Have an autism diagnosis

  • Have a relative, housemate, friend, or other study partner to assist during the study and attend clinic visits

There are additional requirements for participation. The study staff will explain the complete list of requirements.

This study is currently OPEN. Register your interest below. 

Contact CAN Research

Brain and Mind Centre

University of Sydney

94 Mallet Street

Camperdown, NSW, 2050

Tel: 02 9114 4104

Final_CAN_logo_2022 (1).png

The Children’s Hospital at Westmead

Cnr Hawkesbury Road & Hainsworth Street

Westmead, NSW, 2145

We use identity-first language (autistic person)  rather than person-first language (person with autism) throughout the site.
Find out more about our decision to do so. 

 

Privacy Policy

bottom of page